Abstract
Introduction 55
Anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the treatment 56 of neovascular age-related macular degeneration (nAMD). Visual outcomes following anti-57 VEGF therapy [1] [2] [3] [4] have been unparalleled by previous therapies which included laser 58 photocoagulation 5-6 and photodynamic therapy. 7 The effectiveness of anti-VEGF drugs 59 depends, however, on frequent monitoring and early diagnosis of reactivation of the 60 condition. "Fundus fluorescein angiography (FFA) interpreted by an ophthalmologist was in 61 the recent past the reference standard for the detection of active nAMD among those eyes 62 already treated 8, 9 as it directly detects the presence of the active neovascularisation. 63
However, FFA is an invasive and a time-consuming test with, although rare, potentially 64 serious side effects. Other alternative monitoring technologies are available of which the 65 most widely used is optical coherence tomography (OCT)." 66
OCT, including time-domain (TD-OCT) and the most recently developed spectral-domain 67
(SD-OCT), is a light-wave based technology that allows the imaging of the retina and 68 choroid, obtaining "sections" through areas with neovascularisation and surrounding tissues. 69
Scan rates and resolution parameters have greatly improved over the last decade and 70 continue to develop. OCT is a non-invasive, non-contact test typically undertaken by trained 71 medical photographers or technicians and interpreted by ophthalmologists. If OCT were to 72 be able to accurately detect the re-activation of nAMD then FFA would not be needed. 73
The aim of this study was to evaluate the accuracy, interpretability and acceptability 74 of OCT alone or in combination with other tests compared with clinical evaluation of FFA for 75 the detection of active disease in patients with nAMD under treatment and surveillance. 
Methods 80
The target condition was nAMD of any phenotype. Eligible participants were individuals who 81 had been previously treated for nAMD with any type of treatment, and who were monitored 82 to detect active disease. Thus, patients could have active or stable neovascular disease 83 "The index test was OCT, alone or in combination with other tests, i.e., we included studies 84 that used OCT alone or associated with other test or tests to detect nAMD disease activity, 85 including any of the following: clinical evaluation with slit lamp biomicroscopy, visual acuity, 86
Amsler grid, colour fundus photography, infra-red reflectance, red-free images, fundus 87 autofluorescence imaging (FAF), indocyanine green angiography (ICGA), preferential 88 hyperacuity perimetry (PHP) and microperimetry. The reference standard was FFA. 89
Participants were individuals with known, treated nAMD, with any type of treatment, and who 90
were monitored for the condition to detect active disease. We considered direct (head-to-91 head) comparisons in which all participants received the index test, comparator test(s) and 92 the reference standard; indirect comparisons (e.g. case control studies) in which estimates 93 of the accuracy of the respective tests were obtained in different study groups, and 94 randomised controlled trials evaluating effectiveness outcomes where e.g. treatment was 95 based on OCT compared with FFA findings. We also included studies evaluating the 96 acceptability and/or interpretability of the tests. 97
We identified published, unpublished and ongoing studies from searches of electronic 98 independently assessed the risk of bias and applicability concerns of included full-text 117 studies, using an adapted version of the updated quality assessment of diagnostic accuracy 118 studies (QUADAS-2) checklist. 10 The QUADAS-2 checklist is designed to be adapted to the 119 specific review topic. The investigators resolved disagreements by consensus or arbitration 120 by a third reviewer. QUADAS-2 consists of four key domains covering (1) patient selection, 121
(2) index test, (3) reference standard, and (4) flow of patients through the study and timing of 122 the index test(s) and reference standard. Each domain is assessed in terms of the risk of 123 bias. The first three domains are also assessed for concerns regarding their applicability in 124 terms of whether (i) the participants and setting, (ii) index test, its conduct or interpretation 125 and (iii) target condition as defined by the reference standard match the question being 126 addressed by the review. Within each domain signaling questions are included to assist in 127 making a judgment about the risk of bias, with the standard tool containing 11 such 128 questions across the four domains. 129 QUADAS-2 was designed to be adaptable to a specific review topic. For this review, 130 QUADAS-2 was modified by adding an additional signaling question to domain 1 (patient 131 selection) to assess whether participant pre-selection had been avoided. Domains 2 (index 132 test), 3 (reference standard) and 4 (flow and timing) were retained in their entirety. 133
Therefore the modified tool contained 12 signaling questions, with each worded so that a 134 rating of 'Yes' was always optimal in terms of methodological quality. If any signaling 135 questions within a domain were rated 'No' then that domain was judged to be at high risk of 136 bias. With regard to question 9 in the modified tool (appropriateness of the time interval 137 between the index test and the reference standard), it was agreed that to be considered 138 appropriate, the time interval between the index test and reference standard should be no 139 longer than one week." 140
Regarding the statistical analysis we calculated sensitivity and specificity of individual 141 studies when possible. Where two or more studies reported sufficient data we planned to 142 create summary receiver operating characteristic (SROC) curves. We intended to fit meta-143 analysis models using the hierarchical summary receiver operating characteristic (HSROC) 144 model 11 with the SAS software (version 9.1) when possible. We used a symmetric SROC 145 model, as it allows estimation of random effects for the threshold and accuracy effects 146 accounting for the active and non-active sample sizes in each study. We arranged to 147 produce the SROC curves from the HSROC models on the corresponding SROC plots. We 148 planned to report a point estimate and 95% confidence interval (CI) for each model for the 149 summary sensitivity, specificity, positive and negative likelihood ratios and diagnostic odds 150 ratios (DORs). 151
152

Results
153
We identified 4682 titles and abstracts, of which 179 reports were evaluated in full-text 154 (Figure 1) Four studies were judged to be high risk of bias for reasons such as inappropriate exclusions 163 and pre-selection of participants, length of time between the index test and the reference 164 standard, and not all participants being included in the analysis (Figure 2) . All of the 165 monitoring studies were judged to be applicable to our study question. 166
Some studies reported the "eye "as the unit of analysis, i.e., only data of a single 167 examination/comparison of an eye at one point in time was included in the study. Other 168 studies reported an "examination" as the unit of analysis, i.e., a patient or eye was examined 169 several times over a period of time, and the authors included data of several examinations of 170 the same patient and eye. Of the seven studies reporting OCT, five used the eye as the unit 171 of analysis (number of eyes analysed = 363); 12,13,14,18,19 in four of these one eye per patient 172 was analysed (n = 304 eyes). 13 analysis, reported both sensitivity and specificity, providing sufficient data for inclusion in a 184 meta-analysis. Figure 3 shows forest plots of the sensitivity and specificity of the individual 185 studies and SROC curves for (a) all OCT studies, (b) the three TD-OCT studies and (c) the 186 two SD-OCT studies, respectively. Table 2 shows the pooled estimates for these studies. 187
For all OCT studies, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) 188 and 48% (30% to 67%) respectively. For TD-OCT, the pooled sensitivity and specificity 189 (95% CI) was 70% (56% to 80%) and 65% (48% to 79%). For TD-OCT and the group of all 190 four OCT studies the likelihood ratio and DOR values reported were below the level 191 suggestive of strong evidence. It was not possible to calculate pooled estimates for the two 192 SD-OCT studies due to insufficient data. These studies reported sensitivities of 94% 14 and 193
90%
12 and specificities of 27% 14 and 47%, 12 which suggests that SD-OCT has higher 194 sensitivity than TD-OCT but lower specificity. Table 3 ). The study by 203
Giani et al.
14 reported high sensitivity for the detection by SD-OCT of both classic and occult 204 CNV activity (90.9% and 100% respectively). In the studies by Henschel et al. 15 (unit of 205 analysis: examination) and van de Moere et al. 18 (unit of analysis: eye) sensitivity was higher 206 for nAMD activity based on detection of intraretinal fluid (90.3% and 82.9% respectively) 207 compared with subretinal fluid (71.0% and 47.1% respectively). Van de Moere et al. 18 also 208 reported sensitivity of TD-OCT for detection of cystoid macular oedema and pigment 209 epithelial detachment, both low at 22.9% and 5.7% respectively. In the study by Khurana reported 221 information relating to the interpretability of the tests. This TD-OCT study reported that, of 222 136 participants enrolled, 17 (12.5%) were excluded from the analysis due to the poor 223 quality of the OCT or FFA images. The study did not specify how many of these poor quality 224 images were OCT images and how many were FFA. No studies were identified that met our 225 inclusion criteria reporting the acceptability of the tests, either to those providing the tests or 226 to those receiving them. 227
228
Discussion 229
Due to the burden of nAMD to patients and health care providers, an effective and efficient 230 monitoring strategy to detect active disease is needed. The use of frequent (monthly or 231 two-monthly) FFA is not recommended. FFA is hampered by its cost, the fact that it is a 232 relatively time-consuming invasive imaging technology and, although rare, possible risks. 233 Current Preferred Practice Patters by the AAO advise the use of FFA"depending on the 234 clinical findings and judgement of the treating ophthalmologist". 9 OCT is now routinely used 235 for monitoring eyes with nAMD previously treated. 236
We identified a relatively small body of evidence comparing OCT against a reference 237 standard of FFA for the diagnosis of active nAMD in patients under surveillance and treated 238 for this condition. We included eight monitoring studies (all full-text) involving over 400 239 participants. Seven reported the performance of OCT (five TD-OCT, one SD-OCT, one both 240 types) and one the performance of ICGA in the detection of nAMD activity. 241
To compare the performance of diagnostic tests ideally direct comparisons of the accuracy 242 of different tests applied to the same population would be most informative. Alternatively it 243 is possible to evaluate studies of different tests applied to different populations against a 244 common reference standard, using models to indirectly compare tests. In this review four of 245 the OCT studies provided sufficient data for inclusion in a meta-analysis. The pooled 246 sensitivity (95% CI) for all OCT was moderately high at 85% (72% to 93%) but with low 247 specificity at 48% (30% to 67%). For TD-OCT, the pooled sensitivity and specificity was 248 moderate at 70% (56% to 80%) and 65% (48% to 79%) respectively. It was not possible to 249 calculate pooled estimates for the two SD-OCT studies using hierarchical summary receiver 250 operating characteristic (HSROC) methodology due to insufficient data. These studies 251 reported sensitivities of 94% 14 and 90% 12 and specificities of 27% 14 and 47%. 12 Other than 252 OCT, one study reported ICGA, with sensitivity of 75.9% and specificity of 88.0% for the 253 detection of active nAMD. We did not find other studies reporting the performance of 254 alternative technologies. 255
This study suggests that SD-OCT may be more sensitive but less specific in detecting active 256 nAMD than TD-OCT. It is likely that SD-OCT can detect small amounts of fluid in the retina 257 (due to its high resolution) better than TD-OCT. However, fluid does not always indicate 258 active CNV but may indicate RPE malfunctioning, for instance related to RPE atrophy, which 259 has now been recognised to occur frequently in eyes with nAMD undergoing anti-VEGF 260 therapies.
2, 3, 20, 21 Some of the observed heterogeneity among studies results can be 261 explained by the different populations, phenotypes, proportion of active cases, type of 262 treatment, and methodological quality. 263
In terms of strengths of this study, a comprehensive literature search was undertaken and 264 both English and non-English language studies were included. We assessed risk of bias 265 using a modified version of the QUADAS-2 questionnaire, tailored to the needs of this 266 review. We used a robust method, HSROC model, for the analysis, which takes account of 267 the trade-off between true/false positives and models between-study heterogeneity. 22 
268
The reference standard test used for this review was FFA interpreted by an ophthalmologist, 269
and therefore was assumed to have perfect sensitivity and specificity. Consequently it was 270 not possible to address the question of whether OCT might actually be a better test than 271 FFA and have higher sensitivity or specificity than the current reference standard. One 272 approach that has been suggested for determining when a new test should replace the 273 reference standard is that proposed by Glasziou et al. 23 Glasziou et al. suggested the use of 274 a third, 'fair umpire' test, which although potentially less accurate than either the new test or 275 the reference standard, could be considered nonetheless a fair umpire test if its errors were 276 independent of the other tests. 23 However, the authors acknowledged that this would usually 277 be difficult to demonstrate. Unfortunately, none of the included OCT studies involving a third 278 test provided a sufficient level of detail to allow us to explore this approach. 
286
The clinical implications of this review are potentially important as we found evidence of 287 substantial lack of agreement between OCT and FFA to determine activity of nAMD lesions. 288
There are also potential implications regarding the interpretation of results of landmark 289 studies that have used only OCT to guide decisions to treat nAMD, such as the prn arms of 290 the CATT study 2 and the HARBOR study. 26 It is possible the differences in efficacy between 291 monthly and prn arms might be explained in part by a sub-optimal of diagnostic accuracy of 292 OCT to detect active nAMD. 293
In conclusion, our review identified a relatively small number of studies, of variable quality, 294 on the performance of OCT in the monitoring of people with treated nAMD under 295 surveillance to detect disease activity. The available evidence suggests that although OCT 296 is a sensitive test for detecting reactivation of nAMD, it has poor specificity. Consequently, it 297
is not recommended that OCT is used alone to detect reactivation of nAMD in patients under 298
surveillance. According to current evidence OCT should not replace the reference standard 299 of FFA for monitoring patients with nAMD. 300
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